Circio Raises NOK 65 Million in Oversubscribed Rights Issue and Private Placement

Targovax ASA ( (GB:0RIS) ) has shared an announcement.

Circio Holding ASA has completed the final allocation in its oversubscribed rights issue, securing NOK 50 million in gross proceeds through the issuance of 50 million new shares, each accompanied by a warrant, after attracting subscriptions of NOK 77.9 million, 56% above the offer size. To accommodate demand from pre-subscribers who were not fully allocated in the rights issue, the company is also conducting a private placement of 14,992,792 new shares with matching warrants, and issuing a further 2,662,000 commission shares with warrants, bringing total gross proceeds from the combined transactions to approximately NOK 65 million and increasing the share count by nearly 65 million shares. The new shares and warrants from the rights issue, private placement and commission arrangement will be issued and delivered together once payments are received and the capital increase is registered, with the new shares expected to start trading on Euronext Oslo Børs on 10 February 2026, strengthening Circio’s balance sheet as it advances its circRNA technology platform and oncology pipeline.

More about Targovax ASA

Circio Holding ASA is a biotechnology company focused on developing novel circular RNA (circRNA) expression technology for gene and cell therapies. Its proprietary circVec platform is designed to deliver significantly longer RNA half-life and stronger protein expression than conventional mRNA-based viral and non-viral vector systems, targeting applications across genetic medicine, cell therapy and chronic disease. In parallel, the company continues to advance its TG01 immuno-oncology program for RAS-mutated cancers through external academic and industry collaborations in Norway and the United States.

Average Trading Volume: 3,884,203

Current Market Cap: NOK204.5M

Learn more about 0RIS stock on TipRanks’ Stock Analysis page.